- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07711730
Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy (TPCLGMD)
13 juli 2026 bijgewerkt door: University of Deusto
Telecare-Mediated Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
This clinical trial aims to evaluate the efficacy of a telecare-mediated psychosocial and cognitive intervention for children and adolescents aged 7 to 17 with limb-girdle muscular dystrophy.
This group-based intervention (comprising 5 participants) consists of 12 weekly one-hour sessions.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Development and implementation of a psychosocial and cognitive tele-assistance programme for groups of children and adolescents affected by limb-girdle muscular dystrophy.
In this project the variables of interest and intervention include social cognition, quality of life, psychological symptomatology and coping strategies.
The aim of this study is to test whether this programme improves the indicators in the mentioned variables.
Studietype
Ingrijpend
Inschrijving (Geschat)
30
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Biscay
-
Bilbao, Biscay, Spanje, 48007
- Werving
- University of Deusto
-
Contact:
- Óscar Universidad de la Iglesia de Deusto
- Telefoonnummer: -34 944139377
- E-mail: oscar.martinez@deusto.es
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- To be diagnosed with limb-girdle muscular dystrophy
- Being between 7 and 17 years old
- Having signed an informed consent form through their legal guardians prior to participation in the study
- Having Spanish as one of their main languages
- Having access to a computer (with a camera, microphone and speakers integrated) and Internet connection to take part in the videoconferences
Exclusion Criteria:
- Presence of any other diagnosis or sensory deficit that would prevent the application of the tests or hinder the correct performance of the intervention's activities
- Being illiterate
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Controle
Controlegroep wachtlijst
|
The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
|
|
Experimenteel: Intervention
Neuro-psychosocial intervention with 12 groupal sessions is offered
|
The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sociale cognitie - Theory of mind - NEPSY-II
Tijdsspanne: 3 maanden na de interventie
|
De Theory of Mind-subtest van het sociale perceptiedomein van de NEPSY-II in de Spaanse editie (Korkman et al., 2014) beoordeelt figuurlijk taalgebruik, imitatievaardigheden en het vermogen om de gedachten, ideeën en overtuigingen van anderen te begrijpen. Evalueert het vermogen van een persoon om te begrijpen hoe emoties zich verhouden tot de sociale context.
|
3 maanden na de interventie
|
|
Social cognition - Emotion Recognition
Tijdsspanne: 3 months after the intervention
|
Affect Recognition subtest of the Social Perception Domain of the NEPSY-II in the Spanish edition (Korkman et al., 2014) measures the capacity to identify emotions (happy, sad, neutral, afraid, irrationally angry, and disgust) in various images of children.
|
3 months after the intervention
|
|
Social cognition - Theory of mind - Happé's Strange Stories
Tijdsspanne: 3 months after the intervention
|
The Happé's Strange Stories Test is a well-known test of ToM (Happé, 1994; Spanish version: Pousa, 2002).
In this study, we used the White et al. (2009) version that has eight story-types.
This test evaluates participants' capacity to comprehend nonliteral meanings through the reading of brief vignettes.
|
3 months after the intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Health-related quality of life
Tijdsspanne: 3 months after the intervention
|
How an individual's health status impacts their overall well-being and ability to lead a satisfying life The perception of HRQoL is assessed in both healthy and chronically ill children using the Spanish version of the Pediatric Quality of Life Inventory (PedsQLTM 4.0) (Varni et al., 2001).
We used the self-report questionnaire in this study for three age ranges: 5-7, 8-12, and 13-18.
Physical functioning, emotional functioning, social functioning, and academic functioning are the four dimensions covered by the 23-item assessment.
The PedsQL 4.0 provides a physical and a psychosocial summary score in addition to a total score.
It is answered through a likert scale with 5 response options that are then converted into quantitative scores ranging from 0-100 points, with a higher score being a better HRQoL.
|
3 months after the intervention
|
|
Health-related quality of life neuromuscular
Tijdsspanne: 3 months after the intervention
|
How an individual's health status impacts their physical well-being and ability to communicate their disease The perception of HRQoL is assessed in both healthy and chronically ill children using the Spanish version of the Pediatric Quality of Life Inventory Neuromuscular (PedsQLTM Neuromuscular) (Varni et al., 2001).
We used the self-report questionnaire in this study for three age ranges: 5-7, 8-12, and 13-18.
Neuromuscular disease, communication and family functioning are the three dimensions covered by the 25-item assessment.
The PedsQL Neuromuscular provides a physical and a communication skills summary score in addition to a total score.
It is answered through a likert scale with 5 response options that are then converted into quantitative scores ranging from 0-100 points, with a higher score being a better HRQoL.
|
3 months after the intervention
|
|
Children's Depression Inventory-Short
Tijdsspanne: 3 months after the intervention
|
Depression symptoms The Children's Depression Inventory-Short (Kovacs, 1992; Spanish version: Barrio et al. 2012) measures key signs of depression such as sadness, sleep issues, and low self-esteem in just a few.
It is a 10-item self-report questionnaire designed to quickly screen for depressive symptoms in youths aged 7 to 17.
Each choice is scored from 0 to 2, with higher scores reflecting greater symptom severity.
|
3 months after the intervention
|
|
Child Medical Fear
Tijdsspanne: 3 months after the intervention
|
To what children have fear in a medical context The Child Medical Fear scale (Broome et al., 1988; Spanish version: San Martin-Rodriguez et al., 2021) is an assessment tool used to measure a child's anxiety and fear regarding medical events and healthcare environments.
It has 17 items in total, and the scores are rated on a 3-point Likert scale: Not at all (0 points), A little (1 point), and A lot (2 points).
It helps pediatricians and psychologists identify specific triggers-such as physical pain or loss of control-so they can tailor medical care to reduce a child's stress.
|
3 months after the intervention
|
|
Psychopathology
Tijdsspanne: 3 months after the intervention
|
Behavioral and emotional symptoms The Child Behavior Checklist for Ages 6-18 (CBCL/6-18) (Achenbach & Rescorla, 2001) is a multiaxial assessment tool for identifying behavioral and emotional issues in children and adolescents that is aligned with the ASEBA (Achenbach System of Empirically Based Assessment).
It has 113 items total, broken down into eight scales for the following syndromes: anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thinking problems, attention problems, rule-breaking behavior and aggressive behavior.
Scores for internalizing, externalizing, and overall difficulties are also provided by the items.
|
3 months after the intervention
|
|
Strengths and Difficulties Questionnaire
Tijdsspanne: 3 months after the intervention
|
Mental, emotion and behaviour health possible problems The Strengths and Difficulties Questionnaire (Goodman, 1997; Spanish version: García et al., 2000) is a brief behavioral and emotional screening tool for children and adolescents aged 2 to 17.
It uses 25 questions across five categories (emotional symptoms, conduct problems, hyperactivity, peer relationship problems and prosocial behavior) to assess both psychological problems and positive social behaviors.
|
3 months after the intervention
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 maart 2026
Primaire voltooiing (Geschat)
30 december 2026
Studie voltooiing (Geschat)
1 juni 2027
Studieregistratiedata
Eerst ingediend
13 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
13 juli 2026
Eerst geplaatst (Werkelijk)
17 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
13 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Spierziekten
- Neuromusculaire aandoeningen
- Genetische ziekten, aangeboren
- Spieraandoeningen, atrofisch
- Spierdystrofieën
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Gedrag
- Sociaal gedrag
- Spierdystrofieën, ledematengordel
- Sociale vaardigheden
Andere studie-ID-nummers
- PI2026090
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
This plan is open to other reserchers to contact the principal investigator of the study.
IPD-tijdsbestek voor delen
The data is available from now until 2029.
IPD-toegangscriteria voor delen
This plan is open to other reserchers to contact the principal investigator of the study.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .